A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the study drug ASTX727 is an effective treatment
for people who have MPNST with a PCR2 mutation.
ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed
to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and
grow. The study researchers think that the study drug allows decitabine to work better than
decitabine given alone.